Phase I/II trial of Reolysin (reovirus) in combination with carboplatin and paclitaxel in patients with advanced solid tumours (phase 1) and head and neck cancer (phase II).

Trial Profile

Phase I/II trial of Reolysin (reovirus) in combination with carboplatin and paclitaxel in patients with advanced solid tumours (phase 1) and head and neck cancer (phase II).

Completed
Phase of Trial: Phase I/II

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Pelareorep (Primary) ; Carboplatin; Paclitaxel
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Oncolytics Biotech
  • Most Recent Events

    • 12 Sep 2017 Results (n=563) of pooled data from eight trial (NCI-GOG 0186H, NCI-8601, NCIC-CTG IND.213, REO011, REO015, REO016, REO018 and REO021) assessing the safety and tolerability of intravenous pelareorep in combination with chemotherapy, were presented at the 42nd European Society for Medical Oncology Congress.
    • 20 Apr 2012 Status changed from active, no longer recruiting to completed based on presented results.
    • 07 Jun 2010 Updated survival results presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO-2010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top